LAMTOR5 antisense RNA 1 (LAMTOR5-AS1)

LAMTOR5 antisense RNA 1 (LAMTOR5-AS1) is a long non-coding RNA transcribed antisense to the LAMTOR5 gene (located on chromosome 1p13.3), identified primarily in cancer biology research. It is upregulated in chemosensitive cancer cells and downregulated in drug-resistant cells, particularly in osteosarcoma. LAMTOR5-AS1 regulates oxidative stress and multidrug resistance by modulating the NRF2/KEAP1 signaling axis, affecting both the levels and transcriptional activity of NRF2, a key transcription factor in antioxidant responses. It exerts tumor suppressive functions by promoting apoptosis and inhibiting proliferation. LAMTOR5-AS1 also has prognostic value as its expression correlates with patient outcomes in osteosarcoma, prostate cancer, and non-small cell lung cancer. There is experimental evidence suggesting that modulation of LAMTOR5-AS1 alters sensitivity to chemotherapeutic agents (e.g., Etoposide, Carboplatin, Cisplatin) through redox pathway regulation[1][2][4]. No approved drugs currently target this RNA; research into RNA-based therapeutics is ongoing. LAMTOR5-AS1 is not a protein receptor, enzyme, transporter, or transcription factor, but rather part of a growing class of regulatory lncRNAs that influence cell fate and drug response through intricate gene expression networks[1][2][4].

Other names

SLC16A4-AS1LAMTOR5 antisense RNA 1SLC16A4 antisense RNA 1LAMTOR5-AS1

Modulation of NRF2/KEAP1 pathway, affecting cellular redox balance and oxidative stress responses in tumor cells; Regulation of apoptosis and cell cycle via downstream gene targets such as heme oxygenase 1 (HO-1) and thioredoxin reductase 1 (TRX); Impacts chemotherapy response by altering NRF2 transcriptional activity